About Project

Verseon was founded in 2002. Its proprietary drug discovery platform, developed entirely in-house, is the product of over ten years of research and development. The company’s platform is the first systematic, computationally-driven solution to achieve the molecular modelling accuracy necessary for rapid and cost-effective drug discovery.

Verseon plans to use its platform to establish a diversified discovery pipeline across multiple disease areas. Current drug programs include anticoagulation, diabetic macular edema, hereditary angioedema, and oncology (solid tumors).

 

Verseon Corporation is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, computational drug discovery platform to discover new drug candidates that are unlikely to be found using conventional methods. Pairing its computational engines with a comprehensive in-house chemistry and biology workflow, the company has built a growing pipeline of drug programs. Verseon currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.

Team

  • Adityo Prakash, Founder, CEO: Experienced in bringing breakthrough technologies to market; co-founder and former CEO of Pulsent Corp.; inventor on 35 patents; BS, California Institute of Technology
  • Eniko Fodor, Founder, COO : Experienced in building cutting-edge technology organizations with highly effective operating, marketing, and IP strategies; co-founder and former COO of Pulsent Corp.; inventor on 17 patents; BS, Universitatea Babes-Bolyai, Romania
  • David Kita, Founder, Vice President of R&D: Experienced in developing technological solutions in molecular modeling, bioinformatics, and signal processing; former Director of R&D of Pulsent Corp. and Director of Software and Algorithm Development – Bioinformatics at Hyseq Inc; inventor on 16 patents; Ph.D., University of Wisconsin, Madison
  • David Williams, Senior Director of Platform Technology: Experienced in running successful computational physics and chemistry programs; led large research teams in high-energy physics simulations at the Stanford Linear Accelerator Center (SLAC); Ph.D., Massachusetts Institute of Technology
  • Anirban Datta, Senior Director of Discovery Biology: Experienced in cancer cell biology, biochemistry, and novel bio-assay development; elucidated signaling in cancer metastasis at UCSF; co-founded and led development of 3-D cell-culture assays at Pharmacomatrix Inc.; Ph.D., University of Pennsylvania

Advisors

  • Steven Chu, PhD is the former Secretary of Energy from 2009 to 2013. He was awarded the Nobel Prize in Physics in 1997 for his work on laser cooling of atoms at Bell Labs. He has also served on the faculty of University of California, Berkeley and as director of the Lawrence Berkeley National Laboratory from 2004 to 2009. He is currently Professor of Physics and Molecular and Cellular Physiology at Stanford University.
  • John Leonard, MD is the former Senior Vice President, Chief Scientific Officer of AbbVie Inc. Prior to Abbvie, he was the Senior Vice President, Pharmaceutical R&D for Abbott, responsible for guiding Abbot’s research and development efforts including HIV antiviral drugs and other therapies. He completed his internship and residency at Stanford University School of Medicine followed by a post-doctoral fellowship in molecular virology at the National Institute of Allergy and Infectious Diseases.

Asset Details
  • Token Holder Rights
    Profit Share
  • Type of Security
    Stocks
Token Holder Rights

Each security token will be a form of preferred share that grants its holder rights to a percentage of Verseon’s future drug program revenues.

Token Details
  • Ticker
    VERS
Company Profile
  • Legal Name
    Verseon Corporation
  • Company #
    -
  • Company Type
    -
  • Country of Origin
    United States
  • Country of Incorporation
    United States
  • Registered Office
    47071 Bayside Parkway Fremont, California 94538, USA
  • Founder(s)
    Adityo Prakash, Eniko Fodor, David Kita

You May Also Be Interested In